The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis

Ophthalmologica

Volumn 222, Issue 4, 2008, Pages 232-239

  Fujishima, Hiroshi ^a,b   Fukagawa, Kazumi ^b,c   Tanaka, Mari ^d   Uchio, Eiichi ^e   Takamura, Etsuko ^c   Nakagawa, Yayoi ^f   Miyazaki, Dai ^g   Fukushima, Atsuki ^h   Okamoto, Shigeki ⁱ   Yokoi, Norihiko ^j  

^a International University of Health and Welfare Mita Hospital   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d Yatsuekimae Ajisai Eye Clinic   (Japan)

^e FUKUOKA UNIVERSITY   (Japan)

^f Nakagawa Eye Clinic   (Japan)

^g TOTTORI UNIVERSITY   (Japan)

^h KOCHI MEDICAL SCHOOL   (Japan)

ⁱ Okamoto Eye Clinic   (Japan)

^j KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

more..

Author keywords

Allergic conjunctivitis, combined therapy; Chemical mediator release inhibitor; Histamine H1 antagonist

Indexed keywords

EYE DROPS; LEVOCABASTINE; PEMIROLAST; HISTAMINE H1 RECEPTOR ANTAGONIST; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; CHEMOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVAL PAPILLA FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; EYELID EDEMA; FEMALE; HUMAN; KERATOPATHY; LACRIMATION; MALE; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADOLESCENT; CHILD; DRUG COMBINATION; EOSINOPHIL; LEUKOCYTE COUNT; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CONJUNCTIVITIS, ALLERGIC; DRUG THERAPY, COMBINATION; EOSINOPHILS; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PIPERIDINES; PYRIDINES; PYRIMIDINONES; TREATMENT OUTCOME;

EID: 53049103020     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000130072     Document Type: Article

References (28)

1. Manners T: Managing eye conditions in general practice. BMJ 1997;315:816-817.
2. Friedlaender MH: Conjunctivitis of allergic origin: clinical presentation and differential diagnosis. Surv Ophthalmol 1993;38:105-114.
3. Abelson MB: A review of olopatadine for the treatment of ocular allergy. Expert Opin Pharmacother 2004;5:1979-1994.
4. Abelson MB: Comparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl 1999;228:38-42.
5. Mohan R, Muralidharan AR: Steroid induced glaucoma and cataract. Indian J Ophthalmol 1989;37:13-16.
6. Kaye LD, Kalenak JW, Price RL, et al: Ocular implications of long-term prednisone therapy in children. J Pediatr Ophthalmol Strabismus 1993;30:142-144.
7. Frostad AB, Olsen AK: A comparison of topical levocabastine and sodium cromoglycate in the treatment of pollen-provoked allergic conjunctivitis. Clin Exp Allergy 1993;23:406-409.
8. Davies BH, Mullins J: Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis. Allergy 1993;48:519-524.
9. Azevedo M, Castel-Branco MG, Oliveira JF, et al: Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis. Clin Exp Allergy 1991;21:689-694.
10. Odelram H, Björkstén B, af Klercker T, et al: Topical levocabastine versus sodium cromoglycate in allergic conjunctivitis. Allergy 1989;44:432-436.
11. Miyake-Kashima M, Takano Y, Tanaka M, et al: Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Jpn J Ophthalmol 2004;48:587-590.
12. Abelson MB, Berdy GJ, Mundorf T, the Pemirolast Study Group: Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. J Ocul Pharmacol Ther 2002;18:475-488.
13. Katz J, Melzack R: Measurement of pain. Surg Clin North Am 1999;79:231-252.
14. Bielory L, Lien KW, Bigelsen S: Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215-228.
15. Fiscella RG: Topical ocular allergic medication. Managed Care 2002;11:3-7.
16. Dechant KL, Goa KL: Levocabastine: a review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991;41:202-224.
17. Noble S, McTawish D: Levocabastine: an update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Drugs 1995;50:1032-1049.
18. Abelson MB, Weintraub D: Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis. Eur J Ophthalmol 1994;4:91-101.
19. Stokes TC, Feinburg G: Rapid onset of action of levocabastine eye drops in histamine-induced conjunctivitis. Clin Exp Allergy 1993;23:791-794.
20. Minami K, Hossen MA, Kamei C: Increasing effect by simulataneous use of levocabastine and pemirolast on experimental allergic conjunctivitis. Biol Pharm Bull 2005;28:473-476.
21. Abelson MB, Katelaris C, Slugg AP, et al: Ocular immunology; in Abelson M (ed): Allergic Diseases of the Eye. Philadelphia, Saunders, 2000, pp 20-27.
22. Buscaglia S, Paolieri F, Castryllo A, et al: Topical ocular levocabastine reduce ICAM-1 expression on epithelial cells both in vivo and in vitro. Clin Exp Allergy 1996;26:1188-1196.
23. Yanagihara Y, Kasai H, Shida T: Immunopharmacological studies on TBX, a new antiallergic drug. 2. Inhibitory effects on histamine release from peritoneal mast cells and lung fragments of rats. Jpn J Pharmacol 1988;48:103-112.
24. Fujimiya H, Nakashima S, Miyata H, Nozawa Y: Effect of a novel antiallergic drug, pemirolast, on activation of rat peritoneal mast cells: inhibition of exocytotic response and membrane phospholipid turnover. Int Arch Allergy Appl Immunol 1991;96:62-67.
25. Schulman DG, Amdahl L, Washington C, Graves A: A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents. Clin Ther 2003;25:1096-1106.
26. Daniell M, Constantinou M, Vu HT, Taylor HR: Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006;90:461-464.
27. McGill JI, Holgate ST, et al: Allergic eye disease mechanisms. Br J Ophthalmol 1998;82:1203-1214.
28. Mosmann TR, Coffman RL: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different function properties. Annu Rev Immunol 1989;7:145-173.